Massachusetts General Hospital 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases  4 Products   7 Trials   230 News 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Egrifta SV (tesamorelin acetate) / Theratechnologies, Massachusetts General Hospital
NCT03226821: Body Composition and Adipose Tissue in HIV

Completed
4
5
US
Tesamorelin, Egrifta
Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
04/25
04/25
2004-002125-42: EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS

Ongoing
3
12
Europe
Powder and solvent for solution for injection
AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"
EVALUATION OF GROWTH HORMONE RELEASE
 
 
NCT02572323: Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Completed
2
73
US
Tesamorelin, Egrifta
University of California, San Diego, University of Southern California, PalmTree Clinical Research Inc., University of California, San Francisco
Mild Cognitive Impairment
10/23
10/23
NCT03375788: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Active, not recruiting
2
76
US
Tesamorelin, Egrifta, TH9507, Growth Hormone Releasing Hormone Analog, Identical Placebo
Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
07/24
01/25
TRIUMPH, NCT06554717: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

Not yet recruiting
2
100
US
Tesamorelin, Egrifta, TH9507, growth hormone-releasing hormone analogue, Placebo, Exercise
Massachusetts General Hospital, University of Colorado, Denver
HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
01/28
06/28
NCT03150511: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Recruiting
2
36
US
Tesamorelin 2 Milligrams (MG), Egrifta
Johns Hopkins University, United States Department of Defense
Peripheral Nerve Injuries
12/25
12/25
CARv3-TEAM-E T cells / Massachusetts General Hospital
INCIPIENT, NCT05660369: CARv3-TEAM-E T Cells in Glioblastoma

Recruiting
1
21
US
CARv3-TEAM-E T cells, Autologous T lymphocyte
Marcela V. Maus, M.D.,Ph.D.
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
01/26
01/27
NCT05024175: Long-term Follow-up of Subjects Treated with CAR T Cells

Recruiting
N/A
45
US
Disease assessments, Tumor Biopsy, Blood test
Massachusetts General Hospital
Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
08/38
08/39
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Egrifta SV (tesamorelin acetate) / Theratechnologies, Massachusetts General Hospital
NCT03226821: Body Composition and Adipose Tissue in HIV

Completed
4
5
US
Tesamorelin, Egrifta
Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
04/25
04/25
2004-002125-42: EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS

Ongoing
3
12
Europe
Powder and solvent for solution for injection
AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"
EVALUATION OF GROWTH HORMONE RELEASE
 
 
NCT02572323: Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Completed
2
73
US
Tesamorelin, Egrifta
University of California, San Diego, University of Southern California, PalmTree Clinical Research Inc., University of California, San Francisco
Mild Cognitive Impairment
10/23
10/23
NCT03375788: Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Active, not recruiting
2
76
US
Tesamorelin, Egrifta, TH9507, Growth Hormone Releasing Hormone Analog, Identical Placebo
Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
07/24
01/25
TRIUMPH, NCT06554717: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

Not yet recruiting
2
100
US
Tesamorelin, Egrifta, TH9507, growth hormone-releasing hormone analogue, Placebo, Exercise
Massachusetts General Hospital, University of Colorado, Denver
HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
01/28
06/28
NCT03150511: Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

Recruiting
2
36
US
Tesamorelin 2 Milligrams (MG), Egrifta
Johns Hopkins University, United States Department of Defense
Peripheral Nerve Injuries
12/25
12/25
CARv3-TEAM-E T cells / Massachusetts General Hospital
INCIPIENT, NCT05660369: CARv3-TEAM-E T Cells in Glioblastoma

Recruiting
1
21
US
CARv3-TEAM-E T cells, Autologous T lymphocyte
Marcela V. Maus, M.D.,Ph.D.
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
01/26
01/27
NCT05024175: Long-term Follow-up of Subjects Treated with CAR T Cells

Recruiting
N/A
45
US
Disease assessments, Tumor Biopsy, Blood test
Massachusetts General Hospital
Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
08/38
08/39

Download Options